ICM Implantation for Heart Attack
(AID MI Trial)
Trial Summary
What is the purpose of this trial?
Patients post acute myocardial infarction (AMI) have a high risk of mortality but the use of an implantable defibrillator in the early aftermath of an AMI has not been shown to improve patients' survival. The VEST trial recently demonstrated an improved overall survival in post AMI patients with the use of a wearable defibrillator. The same improvement was not demonstrated for the risk of sudden cardiac death. Monitoring patients after AMI using an implantable cardiac monitor (ICM) may document findings that can impact patient management and eventually improve their outcomes. We are therefore conducting the AID MI trial to examine the impact of ICM on patient management in the post AMI setting.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
What data supports the effectiveness of the treatment ICM Implantation for Heart Attack?
Research shows that implantable cardiac monitors (ICMs) are effective in managing heart rhythm problems and improving patient outcomes in heart failure and arrhythmia cases. They help in early detection and management of heart rhythm issues, which can improve quality of life and reduce healthcare costs.12345
Is ICM implantation generally safe for humans?
How does ICM Implantation for Heart Attack differ from other treatments?
ICM (Implantable Cardioverter-Defibrillator) implantation is unique because it provides a preventive therapy for patients at risk of sudden cardiac death after a heart attack by automatically detecting and correcting life-threatening heart rhythms, unlike standard drug therapies that may not address these specific arrhythmias.1112131415
Research Team
Samir Saba, MD
Principal Investigator
University of Pittsburgh Medical Center
Eligibility Criteria
This trial is for adults over 18 who've recently had a heart attack and are expected to leave the hospital within 7 days of the event. They must be willing to get an implantable cardiac monitor (ICM) within 21 days after their heart attack, and agree to give written consent. People with existing heart devices, those pregnant, or needing open-heart surgery can't participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive an implantable cardiac monitor (ICM) and standard of care
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Monitoring
Continued remote monitoring to assess long-term outcomes and patient management
Treatment Details
Interventions
- ICM Implantation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Samir Saba
Lead Sponsor
Abbott
Industry Sponsor
Dr. Etahn Korngold
Abbott
Chief Medical Officer
MD, Harvard Medical School
Robert B. Ford
Abbott
Chief Executive Officer since 2020
Bachelor's degree from Boston College, MBA from UC Berkeley, Haas School of Business